Literature DB >> 2712935

Nemaline myopathy: comparative muscle histochemistry in the severe neonatal, moderate congenital, and adult-onset forms.

C Shimomura1, I Nonaka.   

Abstract

A histochemical study of biopsied muscle specimens from patients with the 3 forms of nemaline myopathy (i.e., severe neonatal, moderate congenital, and adult-onset), classified on the basis of clinical symptoms, was conducted. A close relationship could not be found between the number of rods and the severity of weakness in any form. Type 1 fiber atrophy and predominance or type 2B fiber deficiency was the usual finding in all forms. In the moderate congenital form, type 1 fiber atrophy and predominance became more apparent in patients with a protracted course, suggesting that the histochemical abnormalities are progressive. The abnormal fiber type distribution is assumed to be related to the pathogenetic mechanism of nemaline myopathy in all forms. Because acid phosphatase activity was increased in muscle fibers of patients with rapid progression, an autodegenerative process inducing lysosomal enzyme activation may be responsible for the acute clinical progression and muscle fiber loss in this disorder.

Entities:  

Mesh:

Year:  1989        PMID: 2712935     DOI: 10.1016/0887-8994(89)90005-2

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  12 in total

1.  Progression in nemaline myopathy.

Authors:  I Nonaka; S Ishiura; K Arahata; H Ishibashi-Ueda; T Maruyama; K Ii
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

Review 2.  Nemaline myopathy: current concepts. The ENMC International Consortium and Nemaline Myopathy.

Authors:  K N North; N G Laing; C Wallgren-Pettersson
Journal:  J Med Genet       Date:  1997-09       Impact factor: 6.318

3.  Follow-up studies in a case of unusual congenital myopathy, suggestive of nemaline type.

Authors:  E Gibbels; K Kellermann; H J Schädlich; R Adams; W F Haupt
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

Review 4.  Congenital myopathies: an update.

Authors:  Jessica R Nance; James J Dowling; Elizabeth M Gibbs; Carsten G Bönnemann
Journal:  Curr Neurol Neurosci Rep       Date:  2012-04       Impact factor: 5.081

5.  Genetics of congenital nemaline myopathy: a study of 10 families.

Authors:  C Wallgren-Pettersson; H Kääriäinen; J Rapola; T Salmi; J Jääskeläinen; M Donner
Journal:  J Med Genet       Date:  1990-08       Impact factor: 6.318

6.  Clinical heterogeneity in Korean patients with nemaline myopathy.

Authors:  Ji-Man Hong; Seung-Min Kim; Il-Nam Sunwoo; Se-Hoon Kim; Tai-Seung Kim; Dong-Suk Shim; Young-Chul Choi
Journal:  Yonsei Med J       Date:  2010-02-12       Impact factor: 2.759

7.  Deleting exon 55 from the nebulin gene induces severe muscle weakness in a mouse model for nemaline myopathy.

Authors:  Coen A C Ottenheijm; Danielle Buck; Josine M de Winter; Claudia Ferrara; Nicoletta Piroddi; Chiara Tesi; Jeffrey R Jasper; Fady I Malik; Hui Meng; Ger J M Stienen; Alan H Beggs; Siegfried Labeit; Corrado Poggesi; Michael W Lawlor; Henk Granzier
Journal:  Brain       Date:  2013-05-28       Impact factor: 13.501

8.  KLHL40 deficiency destabilizes thin filament proteins and promotes nemaline myopathy.

Authors:  Ankit Garg; Jason O'Rourke; Chengzu Long; Jonathan Doering; Gianina Ravenscroft; Svetlana Bezprozvannaya; Benjamin R Nelson; Nadine Beetz; Lin Li; She Chen; Nigel G Laing; Robert W Grange; Rhonda Bassel-Duby; Eric N Olson
Journal:  J Clin Invest       Date:  2014-06-24       Impact factor: 14.808

9.  Altered myofilament function depresses force generation in patients with nebulin-based nemaline myopathy (NEM2).

Authors:  Coen A C Ottenheijm; Pleuni Hooijman; Elizabeth T DeChene; Ger J Stienen; Alan H Beggs; Henk Granzier
Journal:  J Struct Biol       Date:  2009-11-26       Impact factor: 2.867

10.  Thin filament length dysregulation contributes to muscle weakness in nemaline myopathy patients with nebulin deficiency.

Authors:  Coen A C Ottenheijm; Christian C Witt; Ger J Stienen; Siegfried Labeit; Alan H Beggs; Henk Granzier
Journal:  Hum Mol Genet       Date:  2009-04-04       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.